• Decrease font size
  • Return font size to normal
  • Increase font size
U.S. Department of Health and Human Services

Search Orphan Drug Designations and Approvals

  • Print
  • Share
  • E-mail
-
Generic Name: a novel CRISPR/Cas13X RNA base-editing therapy drug
Date Designated: 02/29/2024
Orphan Designation: Treatment of OTOF Q829X mutation-induced hearing loss
Orphan Designation Status: Designated
FDA Orphan Approval Status: Not FDA Approved for Orphan Indication
Cholgene Therapeutics, Inc.
651N. Broad Street, Suite 206
Middletown, Delaware 19709
United States

The sponsor address listed is the last reported by the sponsor to OOPD.

*Exclusivity Protected Indications are shown for approvals from 01/01/2013 to the present.
*Data for the Date Designation Withdrawn or Revoked field are shown for designations withdrawn or revoked after 08/12/2013.
-
-